Skip to main content
SpringerLink
Log in

The relation of serum uric acid levels with l-Dopa treatment and progression in patients with Parkinson’s disease

  • Original Article
  • Published:
Neurological Sciences Aims and scope Submit manuscript

Abstract

In this study, we aimed to investigate the association of the serum uric acid (UA) level with disease progression and l-Dopa treatment in PD (Parkinson’s disease) patients. Serum UA levels of 80 consecutive PD patients were measured and were matched according to age and sex with 80 healthy controls. The patients were divided into two subgroups according to the pharmaceutical treatment received. First group consisted of patients treated with l-Dopa and a dopamine agonist and the second group consisted of patients treated only with a dopamine agonist. The patients were divided into two other subgroups according to Hoehn and Yahr scale. First group consisted of patients at the first two stages and the second group included patients at the third and upper stages. PD patients were found to have significantly lower levels of serum UA than controls (p = 0.000). Serum UA levels were lower in the group under l-Dopa + dopamine agonist treatment and in patients at third and upper Hoehn and Yahr stages than the patients under only dopamine agonist treatment and in the patients at the first two stages (p = 0.000 and p = 0.000). Multivariate logistic regression showed that advanced stages (OR 0.65, CI 0.50–0.79, p = 0.000) and l-Dopa treatment (OR 1.08, CI 1.03–1.16, p = 0.001) were independently associated with low UA levels. Our study supports that there is an inverse relation between UA levels and l-Dopa treatment and PD stages, and high serum UA levels may decrease the oxidative stress taking part in the pathogenesis of PD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Samii A, Nutt JG, Ransom BR (2004) Parkinson’s disease. The Lancet 363(9423):1783–1793

    Article  CAS  Google Scholar 

  2. Van der Brug MP, Singleton A, Gasser T, Lewis PA (2015) Parkinson’s disease: From human genetics to clinical trials. SciTransl Med 7(305):205

    Google Scholar 

  3. Cipriani S, Chen X, Schwarzschild MA (2010) Urate: a novel biomarker of Parkinson’s disease risk, diagnosis and prognosis. Biomarkers in Medicine 4(5):701–712

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Whiteman M, Ketsawatsakul U, Halliwell B (2002) A reassessment of the peroxynitrite scavenging activity of uric acid. Ann N Y Acad Sci 962:242–259

    Article  CAS  PubMed  Google Scholar 

  5. Schwarzschild MA, Marek K, Eberly S, Oakes D, Shoulson I, Jennings D, Seibyl J, Ascherio A, Parkinson Study Group PRECEPT Investigators (2011) Serum urate and probability of dopaminergic deficit in early ‘Parkinson disease’. MovDisord 26(10):1864–1868

    Google Scholar 

  6. Ascherio A, LeWitt PA, Xu K et al (2009) Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 66(12):1460–1468

    Article  PubMed  PubMed Central  Google Scholar 

  7. Zhang HN, Guo JF, He D et al (2012) Lower serum UA levels in Parkinson’s disease patients in the Chinese population. Neurosci Lett 514:152–155

    Article  CAS  PubMed  Google Scholar 

  8. Davis JW, Grandinetti A, Waslien CI, Ross GW, White LR, Morens DM (1996) Observations on serum uric acid levels and the risk of idiopathic Parkinson’s disease. Am J Epidemiol 144(5):480–484

    Article  CAS  PubMed  Google Scholar 

  9. Andreadou E, Nikolaou C, Gournaras F et al (2009) Serum uric acid levels in patients with Parkinson’s disease: their relationship to treatment and disease duration. Clinical Neurology and Neurosurgery 111(9):724–728

    Article  PubMed  Google Scholar 

  10. Sun CC, Luo FF, Wei L, Lei M, Li GF, Liu ZL, LE WD, Xu PY (2012) Association of serum uric acid levels with the progression of Parkinson’s disease in Chinese patients. Chinese Med J 125(4):583–587

    CAS  Google Scholar 

  11. Bucay AH (2009) A new hypothesis about the role of uric acid as a neurotransmitter. Med Hypotheses 73:854–865

    Article  Google Scholar 

  12. Shen L, Ji HF (2013) Low uric acid levels in patients with Parkinson’s disease: evidence from meta-analysis. BMJ Open 3:e003620. doi:10.1136/bmjopen-2013-003620

    Article  PubMed  PubMed Central  Google Scholar 

  13. Annanmaki T, Muuronen A, Murros K (2007) Low plasma uric acid level in Parkinson’s disease. Mov Disord 22:1133–1137

    Article  PubMed  Google Scholar 

  14. Bierer DW, Quebbemann AJ (1982) Effect of L-Dopa on renal handling of uric acid. J Pharmacol Exp Ther 223:55–59

    CAS  PubMed  Google Scholar 

  15. Schiess M, Oh I (2008) Serum uric acid and clinical progression in Parkinson disease: potential biomarker for nigrostriatal failure. Arch Neurol 65(6):698–699

    PubMed  Google Scholar 

  16. Moccia M, Pappatà S, Erro R et al (2015) Uric acid relates to dopamine transporter availability in Parkinson’s disease. Acta Neurol Scand. 131(2):127–131

    Article  CAS  PubMed  Google Scholar 

  17. Moccia M, Picillo M, Erro R et al (2014) Is serum uric acid related to non-motor symptoms in de-novo Parkinson’s disease patients? Parkinsonism Relat Disord. 20(7):772–775

    Article  PubMed  Google Scholar 

  18. Moccia M, Picillo M, Erro R et al (2015) Presence and progression of non-motor symptoms in relation to uric acid in de novo Parkinson’s disease. Eur J Neurol. 22(1):93–98

    Article  CAS  PubMed  Google Scholar 

  19. Church WH, Ward VL (1994) Uric acid is reduced in the substantia nigra in Parkinson’s disease: effect on dopamine oxidation. Brain ResBull. 33(4):419–425

    CAS  Google Scholar 

  20. Facheris MF, Hicks AA, Minelli C et al (2011) Variation in the Uric Acid Transporter Gene SLC2A9 and Its Association with AAO of Parkinson’s Disease. J Mol Neurosci 43(3):246–250

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

No funding source was used during the research. No other people than researchers participated in this study.

Author information

Authors and Affiliations

  1. Department of Neurology, Ozel Kas Tıp Merkezi, Istanbul, Turkey

    Eugeniu Vieru

  2. Department of Neurology, Bakirkoy Research and Training Hospital for Neurologic and Psychiatric Diseases, Bakirkoy, 34147, Istanbul, Turkey

    Ayhan Köksal, Belgin Mutluay, Ayten Ceyhan Dirican, Yavuz Altunkaynak & Sevim Baybas

Authors
  1. Eugeniu Vieru
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ayhan Köksal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Belgin Mutluay
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ayten Ceyhan Dirican
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yavuz Altunkaynak
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sevim Baybas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ayhan Köksal.

Ethics declarations

Conflict of interest

We have no potential conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vieru, E., Köksal, A., Mutluay, B. et al. The relation of serum uric acid levels with l-Dopa treatment and progression in patients with Parkinson’s disease. Neurol Sci 37, 743–747 (2016). https://doi.org/10.1007/s10072-015-2471-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-015-2471-z

Keywords

Search

Navigation